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42 (16.0%) patients self monitor their glucose level. The most frequently reported 
factor affecting adherence is high cost of drug therapy, 118 (44.8%), and 
forgetfulness, 99 (37.6%). Most of the patients, 201 (76.4%), have developed one 
complication or the other such as hypertension and glaucoma. CONCLUSIONS: 
There is poor adherence to anti-diabetic therapy among the patients. Financial 
constraint was found to be the most important factor affecting optimal 
adherence to therapy.  
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OBJECTIVES: To examine adherence to oral hypoglycemics among Mississippi 
Medicaid beneficiaries and to evaluate the need for case-mix adjustment when 
examining disparities among counties. METHODS: The study was a retrospective 
analysis of Mississippi Medicaid claims data from 2008-2011. Beneficiaries were 
included in the analysis if they had at least two claims for oral hypoglycemics, 
had 90 or more days of therapy, were at least 18 years old, were not dual-eligible, 
and were not in long term care. Medication adherence was measured using 
Proportion of Days Covered (PDC) with a gap of 60 days being considered a 
discontinuation of therapy. PDC was calculated for each drug being taken and an 
average PDC was computed for each beneficiary for the time on any therapy. 
Beneficiaries with a PDC greater than 80% were considered to be compliant to 
therapy. Overall comorbidity was measured with an RxRisk score. Percentage of 
beneficiaries compliant in each county was calculated. Counties were classified 
as high, medium and low compliance. A multivariable logistic regression model 
was used to assess the relationship between compliance and beneficiaries’ age, 
sex, race and comorbidities. The relationships among county compliance level 
and beneficiary characteristics associated with compliance were evaluated to 
determine case-mix confounders that need to be adjusted for in evaluating 
county level disparities. RESULTS: Percentage of compliant beneficiaries in the 
counties ranged from 33.3% to 66.7%. Beneficiary characteristics related to 
compliance were gender (odds ratio for male to female = 0.870), race (odds ratio 
for African-Americans to Caucasians = 0.647), and RxRisk score (odds ratio for 
score of 0 to 6+ = 0.717). Race and RxRisk scores were significantly related to 
county compliance levels. CONCLUSIONS: Beneficiary characteristics are strong 
predictors of compliance. Any evaluation of county level disparities in adherence 
rates must use adjustments for variations in the patient mix among the 
counties.  
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OBJECTIVES: The association between anti-diabetic adherence, weight loss, and 
glycemic control in patients with type 2 diabetes (T2DM) remains largely 
uncharacterized. This study examined the relationships between these variables 
in T2DM patients in an integrated health system. METHODS: This was a 
historical cohort study of patients treated in the Geisinger Health System. 
Included patients were ≥18 years, with T2DM, prescribed a class of anti-diabetic 
not previously prescribed (index date) between 11/1/10-4/30/11, with HbA1c and 
weight values at index date and 6-months follow-up, and had Geisinger Health 
Plan insurance with ≥1 claim for the index date medication. Anti-diabetics were 
grouped as weight loss (metformin and GLP-1 agonists) versus weight 
gain/neutral (sulfonylureas, thiazolidinediones, DPP-4 inhibitors, insulin, and 
others) to help control for weight effects of drug therapy. Adherence was 
calculated using the modified Medication Possession Ratio (mMPR) with a score 
≥0.8 considered adherent. The primary outcomes were weight loss ≥3% and 
HbA1c control (<7.0%) at 6 months follow-up. A structural equation model (SEM) 
was used to simultaneously assess the associations between claims adherence, 
weight loss, and HbA1c control. RESULTS: There were 166 patients included with 
a mean (SD) age of 61.1 (12.1) years, 56% were women, 98.8% were white, 58 were 
prescribed metformin or a GLP-1, and 108 were prescribed a sulfonylurea, 
thiazolidinedione, DPP-4 inhibitor, insulin, or other class. Adherence per mMPR 
was high with 77.1% of patients classified as adherent with no significant 
difference between anti-diabetic groups. Results of the SEM showed that both 
anti-diabetic adherence (OR 2.71 95%CI 1.22-5.98) and weight loss ≥3% (OR 2.99 
95%CI 1.45-6.17) were associated with HbA1c control. CONCLUSIONS: This study 
adds to the body of literature highlighting the importance of weight loss and 
adherence in glycemic control. It also emphasizes the importance of anti-
diabetic agent selection and strategies promoting adherence and weight 
management goals.  
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OBJECTIVES: The Morisky Medication Adherence Scale (MMAS) provides a 
unique perspective on adherence because of its patient-reported nature. 
However, as it is not a condition-specific instrument, evidence of its reliability 
and validity within the population of interest must be obtained. This study 
examined the psychometric properties of the recently developed eight-item 
MMAS (MMAS-8) among those with type 2 diabetes (T2D) using insulin. 
METHODS: Data from the US 2012 National Health and Wellness Survey (NHWS) 
were used (N=71,141). Only respondents who reported a diagnosis of T2D, were 
currently using an insulin (any type), and reported their last value of HbA1c were 
included (n=1,198). Among this subsample, the reliability and validity of the 
MMAS-8 (when asked only about diabetes medications) were examined using 
both classic test theory and item response theory (IRT) analyses. RESULTS: A 
total of 61.44% of respondents were male and the mean age was 60.65 (standard 
deviation = 10.74). Engagement of non-adherent behaviors (the individual items 
of the MMAS-8) varied considerably from “stopping medication when feeling 
worse” (5.76%) to “having difficulty remembering to take all your medications” 
(32.22%). Internal consistency was adequate (Cronbach’s α=0.68), though would 
have been improved upon removal of the “did you take your medicine yesterday” 
item (α=0.70 if removed). One factor was retained using exploratory factor 
analysis (eigenvalue=1.80). In IRT analyses, most items exhibited solid 
psychometric properties (e.g., discrimination > 1.40); however, “did you take your 
medicine yesterday”, provided little information (discrimination=0.20; 
information=0.02). Overall, the MMAS-8 functioned best when distinguishing 
among those with above average non-adherence (Θ>0). CONCLUSIONS: These 
results suggest the MMAS-8 is a reliable and valid instrument to use to assess 
non-adherence, though certain items are less useful than others for this 
population. Despite its generic nature, the MMAS-8 should be considered as an 
adherence measurement tool among those with T2D using insulin.  
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OBJECTIVES: Patients with type-2 diabetes mellitus (T2DM) are at increased risk 
of stroke or myocardial infarction (MI) resulting in decrements in their health-
related quality of life. A systematic literature review identified estimates of 
utility decrements for these events in patients with T2DM to better understand 
the impact of avoiding or delaying them with treatment. METHODS: Electronic 
databases (2001-2011) and conference abstracts (2009-2011) in English were 
searched for utility-elicitation studies in T2DM and for cost-effectiveness 
analyses that included disutility estimates for stroke and MI. RESULTS: Nine 
utility-estimation studies using data from 11 countries were identified. Seven of 
these studies presented results adjusted for confounding variables including age 
and other comorbidities. Of those, two also adjusted for time since the event or 
event severity. Disutilities ranged from 0.035 to 0.129 for MI and from 0.044 to 
0.269 for stroke. One study presented disutilities for an event experienced the 
previous year (MI, 0.081 - 0.129; stroke, 0.091 - 0.181) and >1 year ago (MI, 0.042 - 
0.078; stroke, 0.069 - 0.269). The study presenting estimates by event severity 
adjusted for confounding variables had disutilities of 0.044 for stroke or transient 
ischemic attack without disability and 0.072 for stroke with residual disability. Of 
the 15 economic evaluations identified that included estimates of disutilities for 
MI and/or stroke, 12 used values from one of the utility-estimation studies 
described above. Two used disutilities from US studies in patients with any type 
of diabetes, and one used general population disutilities. CONCLUSIONS: The 
wide range of utility estimates for MI or stroke in T2DM patients could impact 
the results of cost-effectiveness analyses for new treatments that avoid or delay 
these events and calls for research to create consistent estimates, accounting for 
event severity and valuing event sequelae over time, such as poststroke 
disability.  
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OBJECTIVES: To assess prevalence and type of Patient-Reported Outcomes 
(PROs) in Type 2 Diabetes clinical trials. METHODS: A search of 
www.clinicaltrials.gov was conducted using the search criteria of Type-2 
diabetes (T2DM) as the disease and drug as the intervention, in addition to 
limiting the studies to Phase 3. This resulted in 810 trials. Trials were excluded if 
any of the following exclusion criteria were met: sample size <50, start date 
before 2000, main condition other than T2DM, and trial did not include clinical 
outcomes. Phase 2/3 studies, pediatrics trials, and both double-blind and open-
label studies were included. The remaining 632 trials were then assessed  
for prevalence and type of PROs. RESULTS: Only 47 (7.4%) of trials in the sample 
used PROs. There is no discernable trend for PRO use over time. For these  
47 trials, 1.9 PROs were used on average, with a range of 1 to 7 PROs. A total of  
90 PROs were included in these 47 trials. Forty-three (48%) of these PROs 
measured Health-Related Quality of Life (HRQL)/Utilities, 22 (24%) measured 
treatment satisfaction, five (6%) were unknown. Within the HRQL measures,  
37% (16) were diabetes-specific, 37% (16) were generic (e.g., SF-36), and the 
remaining 26% of PROs were not specified. Among treatment satisfaction, 82% 
were diabetes-specific. Thirty-three (70%) of the studies using PROs were for 
drugs that are injectables (i.e., not oral). CONCLUSIONS: PRO use in T2DM 
clinical trials remains low. Despite their underuse, the need to assess 
effectiveness of an intervention from a patient perspective continues to grow in 
relevance. Although there are a host of diabetes-specific PROs available, the 
development of a clinical trial-specific, user-friendly instrument may be needed 
